Patents by Inventor Charles Murry

Charles Murry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9994812
    Abstract: The present invention generally relates to the field of cell growth and tissue engineering, in particular, tissue engineered compositions comprising a nanotextured substrate which is structurally configured for growth of cells in an anatomically correct adult phenotype in vitro. In particular, described herein are nanotextured substrates which are structurally configured for the anisotropic organization, maturation, and growth of in vitro-differentiated muscle cells, such as cardiomyocytes, and methods for the production and use thereof in varying sizes, nanotextures and substrate rigidities. In vitro-differentiated cardiomyocytes grown on the nanotextured substrates described herein are better-differentiated and more closely mimic adult cardiac tissue than the same cells grown on a non-textured substrate of the same composition.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 12, 2018
    Assignee: University of Washington through Its Center For Commercialization
    Inventors: Deok-Ho Kim, Michael Laflamme, Charles Murry, Kshitiz Gupta, Hyok Yoo, Alex Jiao
  • Patent number: 9868937
    Abstract: Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: January 16, 2018
    Assignee: University of Washington
    Inventors: Michael Regnier, Michael Laflamme, Charles Murry, F. Steven Korte, Scott Lundy, Stephen Denison Hauschka, Jeffrey S. Chamberlain, Guy Odom
  • Publication number: 20160186139
    Abstract: Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.
    Type: Application
    Filed: May 29, 2012
    Publication date: June 30, 2016
    Applicant: University of Washington
    Inventors: Michael Regnier, Michael Laflamme, Charles Murry, F. Steven Korte, Scott Lundy, Stephen Denison Hauschka, Jeffrey S. Chamberlain
  • Publication number: 20160015860
    Abstract: In some embodiments, a micro-tissue particle comprising a scaffold-free population of aggregated cells is provided. The micro-tissue particle may have a diameter less than approximately 1 mm. In some aspects the diameter is less than approximately 500? m. The population of cells may include at least one terminally differentiated cell type. In one aspect, the population of cells may include cardiomyocytes, endothelial cells, smooth muscle cells, mesenchymal stem cells, or a combination thereof. The micro-tissue particle may be used to treat or regenerate an injured, degenerated or diseased tissue. For example, micro-tissue particles that include cardiomyocytes may be administered to myocardial tissue that has been injured due to a myocardial infarction.
    Type: Application
    Filed: February 15, 2013
    Publication date: January 21, 2016
    Inventors: Charles Murry, Kareen Louise Kreutziger
  • Publication number: 20150125952
    Abstract: The present invention generally relates to the field of cell growth and tissue engineering, in particular, tissue engineered compositions comprising a nanotextured substrate which is structurally configured for growth of cells in an anatomically correct adult phenotype in vitro. In particular, described herein are nanotextured substrates which are structurally configured for the anisotropic organization, maturation, and growth of in vitro-differentiated muscle cells, such as cardiomyocytes, and methods for the production and use thereof in varying sizes, nanotextures and substrate rigidities. In vitro-differentiated cardiomyocytes grown on the nanotextured substrates described herein are better-differentiated and more closely mimic adult cardiac tissue than the same cells grown on a non-textured substrate of the same composition.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 7, 2015
    Inventors: Deok-Ho Kim, Michael Laflamme, Charles Murry, Kshitiz Gupta, Hyok Yoo, Alex Jiao
  • Publication number: 20070166288
    Abstract: The survival of cells during transplantation is enhanced. Cells to be transplanted are administered in a formulation that provides two ore more survival enhancing factors. Optionally, prior to administration, the cells are cultured in the presence of factors that enhance survival, and may be heat shocked prior to transplantation.
    Type: Application
    Filed: January 19, 2006
    Publication date: July 19, 2007
    Inventors: Charles Murry, Michael Laflamme
  • Publication number: 20060040389
    Abstract: Viable differentiating cells from in vitro cultures of stem cells are selected for by partial dissociation to provide cell aggregates. Aggregates comprising cells of interest are selected for phenotypic features using methods that substantially maintain the cell to cell contacts in the aggregate.
    Type: Application
    Filed: August 17, 2004
    Publication date: February 23, 2006
    Inventors: Charles Murry, Michael Laflamme